Concepedia

John Valliere‐Douglass

JV

22

Publications

1.4K

Citations

19

H-Index

2007

Active since

Affiliations

Amgen (United States)(Current)

Seagen (United States)

Fred Hutch Cancer Center

John Valliere‐Douglass is an author at Amgen (United States) specializing in medicine, antibody engineering, and mass spectrometry.

Top concepts

MedicineAntibody EngineeringBioanalysisNatural SciencesMass SpectrometryBiochemistryProtein EngineeringImmunologyChromatographyAnalytical Chemistry

Publications per year

2007–2019

22

Publications

22

Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain

Boxu Yan, Sean Steen, David M. Hambly et al. · Journal of Pharmaceutical Sciences · 2009 · 168 citations

Succinimide Formation, Asn 55, Immunocytochemical Technique +12

Native Intact Mass Determination of Antibodies Conjugated with Monomethyl Auristatin E and F at Interchain Cysteine Residues

John Valliere‐Douglass, William A. McFee, Oscar Salas‐Solano · Analytical Chemistry · 2012 · 142 citations

Immunocytochemical Technique, Interchain Cysteine Residues, Monomethyl Auristatin E +22

Resolving Disulfide Structural Isoforms of IgG2 Monoclonal Antibodies by Ion Mobility Mass Spectrometry

Dhanashri Bagal, John Valliere‐Douglass, Alain Balland et al. · Analytical Chemistry · 2010 · 101 citations

Analysis of post-translational modifications in recombinant monoclonal antibody IgG1 by reversed-phase liquid chromatography/mass spectrometry

Boxu Yan, John Valliere‐Douglass, Lowell J. Brady et al. · Journal of Chromatography A · 2007 · 100 citations

Post-translational Modifications, Bioanalysis, Mass Spectrometry +9

Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia

Fu Li, May Kung Sutherland, Changpu Yu et al. · Molecular Cancer Therapeutics · 2017 · 94 citations

Rows per page

1–5 of 22